67980-77-2

Basic information

• Product Name: 1-(3-Pyridinyl)piperazine
• Synonyms: 1-PYRIDIN-3-YL-PIPERAZINE;1-(3-Pyridinyl)piperazine;1-pyridin-3-ylpiperazine(SALTDATA: 2HBr);1-pyridin-3-ylpiperazine 2HBr;BUTTPARK 82\08-04;CHEMBRDG-BB 4004211
• CAS NO: 67980-77-2
• Molecular Formula: C₉H₁₃N₃
• Molecular Weight: 163.22
• Product Categories: pharmacetical
• Mol File: 67980-77-2.mol
• Article Data: 21

Chemical Properties

• Melting Point: 48-52°C
• Boiling Point: 314.396 °C at 760 mmHg
• Flash Point: 143.942 °C
• Appearance: /
• Density: 1.081 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.547
• Storage Temp.: 2-8°C(protect from light)
• PKA: 8.70±0.10(Predicted)
• CAS DataBase Reference: 1-(3-Pyridinyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-Pyridinyl)piperazine(67980-77-2)
• EPA Substance Registry System: 1-(3-Pyridinyl)piperazine(67980-77-2)

Safety Data

• Hazardous Substances Data: 67980-77-2(Hazardous Substances Data)

Usage

Description

1-(3-Pyridinyl)piperazine, also known as 3-PP or mCPP, is a piperazine derivative that serves as a research chemical and psychoactive drug. It exhibits stimulant and entactogenic effects due to its action as a serotonin receptor agonist and a norepinephrine reuptake inhibitor. Despite its potential for abuse and associated side effects, 1-(3-Pyridinyl)piperazine remains a subject of study for its pharmacological properties and possible medical applications.

Uses

Used in Pharmaceutical Research:
1-(3-Pyridinyl)piperazine is used as a research chemical for studying its pharmacological properties and potential therapeutic applications. Its dual action as a serotonin receptor agonist and a norepinephrine reuptake inhibitor makes it a valuable compound for exploring the mechanisms of action in various neurological and psychiatric disorders.
Used in Psychopharmacology:
In psychopharmacology, 1-(3-Pyridinyl)piperazine is used as a psychoactive drug with stimulant and entactogenic effects. Its ability to modulate serotonin and norepinephrine levels in the brain contributes to its potential use in the treatment of mood disorders and other conditions related to neurotransmitter imbalances.
However, it is important to note that due to its potential for abuse and adverse health effects, 1-(3-Pyridinyl)piperazine has been banned in some countries. Further research is needed to fully understand its safety profile and potential medical applications.

InChI:InChI=1/C9H13N3/c1-2-9(8-11-3-1)12-6-4-10-5-7-12/h1-3,8,10H,4-7H2

Upstream product

• 626-55-1 3-Bromopyridine 
• 110-85-0 piperazine 
• 372-47-4 3-Fluoropyridine 
• 13716-12-6 tri-tert-butyl phosphine 
• 865-48-5 sodium t-butanolate 
• 462-08-8 pyridin-3-ylamine 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 
• 223797-47-5 1-(pyridin-3-yl)-4-tert-butoxycarbonylpiperazine 
• 13480-30-3 1-benzyl-4-(3'-pyridinyl)piperazine 

Downstream Products

• 112940-59-7 1-(4-nitrophenyl)-4-pyridin-3-ylpiperazine 
• 223797-47-5 1-(pyridin-3-yl)-4-tert-butoxycarbonylpiperazine 

Relevant articles and documents

Dopamine D4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuning.

A series of subtype selective dopamine D(4) receptor ligands from the hetroarylmethylphenylpiperazine class have been discovered that exhibit a remarkable structure-activity relationship (SAR), revealing a substituent effect in which regiosubstitution on the terminal arylpiperazine ring can modulate functional or intrinsic activity. Other structure-dependent efficacy studies in the dopamine D(4) field have suggested a critical interaction of the heteroarylmethyl moiety with specific protein microdomains in controlling intrinsic activity. Our studies indicate that for some binding orientations, the phenylpiperazine moiety also plays a key role in determining efficacy. These data also implicate a kinetic or efficiency term, contained within measured functional affinities for agonists, which support a sequential binding and conformational stabilization model for receptor activation. The structural similarity between partial agonist and antagonist, within this subset of ligands, and lack of bioisosterism for this substituent effect are key phenomena for these hypotheses.

Exploration of the molecular architecture of the orthosteric binding site in the α4β2 nicotinic acetylcholine receptor with analogs of 3-(dimethylamino)butyl dimethylcarbamate (DMABC) and 1-(pyridin-3-yl)-1,4-diazepane

X-ray crystal structures of acetylcholine binding proteins (AChBPs) have revealed two different possible extensions to the classical ligand binding pocket known to accommodate various nicotinic agonists. One of the pockets is limited in size while the oth

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.